Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial

Fig. 1

Overall survival rate after CRS + HIPC with cisplatin for peritoneal carcinomatosis from gastric cancer Group A: PCI </= 12 without PC on any small bowel region with 4 or more non-small bowel regions. Group B: PCI >/= 13 with PC on any small bowel with 4 or more non-small bowel regions. CRS + HIPC cytoreductive surgery plus hyperthermic intra-operative peritoneal chemotherapy; PC peritoneal carcinomatosis; PCI peritoneal carcinomatosis index

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us